Dr Palak Trivedi BSc (hons), MBBS, MRCP Gastro (UK), PhD

Palak Trivedi

Institute of Immunology and Immunotherapy
Associate Professor and Honorary Consultant Hepatologist
Clinical Research Director for Industry Engagement

Contact details

NIHR Birmingham BRC
Centre for Liver and Gastrointestinal Research
Institute of Immunology and Immunotherapy
ITM Building, Mindelsohn Way
University of Birmingham
B15 2TT

Dr. Trivedi is a Clinician Scientist in the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), based at the University of Birmingham. Dr. Trivedi is a Consultant Hepatologist who has devoted his clinical and research career to studying immune-mediated and chronic cholestatic liver disease, specifically primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Palak is chief investigator for the UK-PSC consortium, and was elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease in 2018.


  • PhD in liver Immunology, University of Birmingham, 2015
  • Member of the Royal College of Physicians, London, 2008
  • MBBS, St. George’s Hospital Medical School, London, 2005
  • BSc (hons) in Medical Genetics, St. George’s Hospital Medical School, London, 2012


Palak completed his PhD in Liver Immunology in 2015, securing a competitively awarded Wellcome Trust Clinical Research Fellowship. During this time, his work on risk stratification in PBC was ranked the highest scoring clinical abstract at the EASL International Liver Congress.

Palak went on to receive the Investigator of the Year award in 2017 for work on gut-liver immunity in PSC, was recipient of the Andy Burroughs’ prize for best Hepatology research at the British Association for Study of the Liver (BASL), and won the Elwyn Elias prize for research into PSC and liver transplantation the same year. Palak is currently a mid-career researcher at the University of Birmingham, with 50% protected research time and the remainder dedicated to clinical practice.

Palak currently leads the PBC and PSC clinical research programme, with the overarching themes of work focussing on the role of gut-liver immunity, modelling the natural history of PBC and PSC, generating real-world clinical outcome data, and risk stratification pre- and post-transplantation.


  • Lead for the year 4 and 5 gastroenterology and hepatology MBChB programme

Postgraduate supervision

Post-doc supervision

  • Dr. Scott Davies
  • Dr. Hannah Crothers

MD/PhD supervision

  • Dr. Nadir Abbas
  • Dr. Sheeba Khan


  • Exercise intervention to attenuate symptoms in cholestasis
  • Epidemiology of primary sclerosing cholangitis
  • Risk stratification in chronic cholestatic liver disease
  • Characterising the natural history of PBC and PSC
  • Gut-liver immunity in the pathogenesis of autoimmune liver disease
  • Clinical trial design in rare disease
  • Immune-therapy induced liver injury
  • Exploring stability and function of regulatory T cells in human livers to develop and deliver immunotherapy for autoimmune hepatitis


Recent publications


Trivedi, PJ, Crothers, H, Mytton, J, Bosch, S, Iqbal, T, Ferguson, J & Hirschfield, GM 2020, 'Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel diseases, based on sex, race, and age', Gastroenterology, vol. 159, no. 3, pp. 915-928. https://doi.org/10.1053/j.gastro.2020.05.049

International Primary Sclerosing Cholangitis Study Group (IPSCSG) 2020, 'Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases', Clinical Gastroenterology and Hepatology, vol. 18, no. 1, pp. 179-187.e6. https://doi.org/10.1016/j.cgh.2019.05.013

Global PBC Study Group 2020, 'Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase', The American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000557

Trivedi, PJ, Muir, AJ, Levy, C, Bowlus, CL, Manns, M, Lu, X, Crans, G, Chung, C, Subramanian, GM, Myers, RP, Goodman, Z, Chalasani, N, Vierling, JM, Guha, IN & Hirschfield, GM 2020, 'Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis', Clinical Gastroenterology and Hepatology, vol. 2020. https://doi.org/10.1016/j.cgh.2020.07.032

Global PBC Study Group 2020, 'Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.03.043

Chapman, RW, Aspinall, RJ, Trivedi, P, Wright, G & Heneghan, M 2019, 'Challenges in the use of corticosteroids in the management of autoimmune hepatitis', British journal of hospital medicine, vol. 80, no. 10, pp. 594-599. https://doi.org/10.12968/hmed.2019.80.10.594

Global PBC Study Group 2019, 'Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis', Clinical Gastroenterology and Hepatology, vol. 17, no. 10, pp. 2076-2084.e2. https://doi.org/10.1016/j.cgh.2018.12.028

UK-PSC Consortium 2019, 'Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system', Hepatology, vol. 69, no. 5, pp. 2120-2135. https://doi.org/10.1002/hep.30479

Global PBC Study Group 2019, 'Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival', Gastroenterology, vol. 156, no. 1, pp. 96-107.e1. https://doi.org/10.1053/j.gastro.2018.10.001

Global PBC Study Group 2019, 'Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response', Alimentary Pharmacology & Therapeutics, vol. 50, no. 10, pp. 1127-1136. https://doi.org/10.1111/apt.15533

Harms, MH, de Veer, RC, Lammers, WJ, Corpechot, C, Thorburn, D, Janssen, HLA, Lindor, KD, Trivedi, PJ, Hirschfield, GM, Pares, A, Floreani, A, Mayo, MJ, Invernizzi, P, Battezzati, PM, Nevens, F, Ponsioen, CY, Mason, AL, Kowdley, KV, Hansen, BE, Buuren, HRV & van der Meer, AJ 2019, 'Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis', Gut. https://doi.org/10.1136/gutjnl-2019-319057

Lemoinne, S, Cazzagon, N, El Mouhadi, S, Trivedi, PJ, Dohan, A, Kemgang, A, Ben Belkacem, K, Housset, C, Chretien, Y, Corpechot, C, Hirschfield, G, Floreani, A, Motta, R, Gallix, B, Barkun, A, Barkun, J, Chazouillères, O & Arrivé, L 2019, 'Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis', Clinical Gastroenterology and Hepatology, vol. 17, no. 13, pp. 2785-2792.e3. https://doi.org/10.1016/j.cgh.2019.03.013

Cazzagon, N, Lemoinne, S, El Mouhadi, S, Trivedi, PJ, Gaouar, F, Kemgang, A, Ben Belkacem, K, Floreani, A, Hirschfield, G, Chretien, Y, Housset, C, Motta, R, Russo, FP, Chazouillères, O, Arrivé, L & Corpechot, C 2019, 'The complementary value of magnetic resonance imaging and vibration-controlled transient elastography for risk stratification in primary sclerosing cholangitis', The American Journal of Gastroenterology, vol. 114, no. 12, pp. 1878-1885. https://doi.org/10.14309/ajg.0000000000000461


Trivedi, P 2019, 'Risk stratification in primary sclerosing cholangitis: it’s time to move on from replicating imperfection and break the glass ceiling', Journal of Hepatology, vol. 71, no. 5, pp. 867-870. https://doi.org/10.1016/j.jhep.2019.08.013, https://doi.org/https://www.journal-of-hepatology.eu/article/S0168-8278(19)30480-5/fulltext

Armstrong, MJ, Mellinger, JL & Trivedi, PJ 2018, 'Alcohol consumption in patients with non-alcoholic fatty liver disease: convenient vs. inconvenient truths', The American Journal of Gastroenterology, vol. 113, no. 10, pp. 1437-1439. https://doi.org/10.1038/s41395-018-0237-y

View all publications in research portal

Culture and collections

Schools, institutes and departments

Services and facilities